A New Nanoparticle Vaccine Effective at Single Dose for SARS-CoV-2

A vaccine developed by researchers at Stanford University contains nanoparticles studded with the same proteins that comprise the virus’s distinctive surface spikes. The advantage of nanoparticle-based vaccines is they balance the effectiveness of viral-based vaccines with the safety and ease-of-production of subunit vaccines.

Initial tests in mice suggest that the Stanford nanoparticle vaccine could produce COVID-19 immunity after just one dose. For the mouse tests, the researchers compared their shortened spike nanoparticles to four other potentially useful variations: nanoparticles with full spikes, full spikes or partial spikes without nanoparticles, and a vaccine containing just the section of the spike that binds to cells during infection. They used pseudo-coronavirus that was modified to carry SARS-CoV-2’s spike.

After a single dose, the two nanoparticle vaccine candidates both resulted in neutralizing antibody levels at least twice as high as those seen in people who have had COVID-19, and the shortened spike nanoparticle vaccine produced a significantly higher neutralizing response than the binding spike or the full spike (non-nano particle) vaccines. After a second dose, mice that had received the shortened spike nanoparticle vaccine had the highest levels of neutralizing antibodies.

To know more about origin, virology of COVID-19, Click here

To know more about emerging themes in COVID-19, Click here

To know more about how WhiteCoats can help you in your professional advancement, visit www.whitecoats.com

Want to set up an online consultation for your practice, Click here

Ref link: https://pubs.acs.org/doi/10.1021/acscentsci.0c01405

#Featured